socaltech.com
San Diego-based
Pipeline Therapeutics, a biopharmaceuticals firm focused on small molecules for neuroregeneration, said on Thursday that it has raised $80M in its Series C funding. The funding included Perceptive Advisors, Franklin Templeton, Casdin Capital, Samsara BioCapital, Suvretta Capital, Red Tree Venture Capital, plus Versant Ventures, Sectoral Asset Management, Cleva Pharma (a Brace Pharma affiliate), Hadean Ventures, RBV Capital and Helicase Venture, as well as several other undisclosed investors. The lead was a healthcare-focused new investor , according to the company. The company said it will use the new funding to advance development candidates for a number of its programs. Pipeline Therapeutics is led by President and CEO Carmine Stengone.
AstraZeneca plans to roll out variant-resistant vaccine this autumn
The company is working with the University of Oxford to roll out the new vaccine Getty Images Thursday February 11, 2021 12:34 pm
UK pharmaceutical giant AstraZeneca said it is on course to roll out a variant-resistant Covid-19 vaccine in the autumn this year, as clinical trials begin this spring.
The FTSE 100 company announced the schedule as it unveiled its annual results, reported on 11 February.
“In collaboration with the University of Oxford, AstraZeneca is focused.
Biocon rose 1.04% to Rs 413.90 after the company s subsidiary signed an agreement with the Clinton Health Access Initiative (CHAI) to expand access to lifesaving cancer biosimilars in over 30 countries in Africa and Asia.Biocon Biologics, a fully integrated pure play biosimilars company and a subsidiary of Biocon, has signed an agreement with the Clinton Health Access Initiative (CHAI) to expand access to lifesaving cancer biosimilars in over 30 countries in Africa and Asiaas a part of the Cancer Access Partnership (CAP).
The partnership is a significant step in delivering advanced cancer therapies to patientswho need them the most and ensuring equitable access to high-quality biosimilars in low-and middle-income countries (LMICs).
PhaseBio Pharmaceuticals, Inc.: PhaseBio Announces Dosing of First Patient in European Union as Part of REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor
with antiplatelet therapy being a core treatment to prevent cardiovascular events
The lack of reversal agents for patients taking antiplatelet therapies who require urgent surgery or experience a major bleeding event remains a critical unmet need
Bentracimab (PB2452) has demonstrated immediate and sustained reversal of the antiplatelet effects of ticagrelor in both Phase 1 and Phase 2 clinical trials PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that in conjunction with its financing and co-development partner for the European Union and China, SFJ Pharmaceuticals, PhaseBio has expanded its pivotal Phase 3 REVERSE-IT trial
커뮤니티
조회수: 6,864
LOCATION:
Commerce, CA
JOB DUTIES include but are not limited to the following:
• Promoting business development opportunities
• Presenting company brand to potential clients
• Finding and developing new markets and improving brand awareness
• Building long-term trusting relationships with clients
• Reporting to the Business development on (Weekly/Monthly) development processes and results
QUALIFICATIONS
• Experience in sales, marketing or related field
• 1 - 2 years relevant work experience in business development, sales or similar field preferred
• Excellent written and verbal communication skills
• Ability to handle multiple projects simultaneously and work under pressure
• Strong organization and project management skills
• Friendly and personable demeanor
• English/Korean Bilingual